Huons Meditech, a medical device affiliate of Huons Group, said Tuesday it started exporting its gynecological drug delivery system Jill’SOF and its dedicated microneedle V-needle to Taiwan, following approval from the Taiwan Food and Drug Administration (TFDA).

Jill’SOF is an electrically powered system designed to treat vaginal dryness. It allows healthcare providers to control the drug dosage and speed for tailored treatments.

The V-needle, a disposable microneedle used in conjunction with Jill’SOF, delivers the medication safely and effectively into the target area. The procedure takes about 10 minutes and is virtually painless, eliminating the need for sedation and allowing patients to quickly resume daily activities.

“This marks our first overseas approval and export of Jill’SOF, making the TFDA’s authorization especially meaningful,” said Huons Meditech CEO Lee Jin-suk. “We aim to boost Jill’SOF’s presence in the global gynecological device market, starting with Taiwan.”

Huons Meditech is also preparing to launch a new model, Jill’SOF Queen, which integrates drug delivery capabilities with aesthetic technologies from its Dermashine line. The company expects to receive TFDA approval for the upgraded device later this year.